We'll share data: Russia's Sputnik V Covid vaccine scientists respond to published doubts

Developers of Russian COVID-19 vaccine Sputnik V have responded to widespread criticism and suspicion over vaccine's human trials and about it being put to use before its phase 3 trials, in British medical journal Lancet.

This occurred after western researchers raised suspicion over vaccine in British medical journal and called on Russian developers to respond to queries raised by ir peers.

READ | Russia's COVID-19 Vaccine 'Sputnik V' Touted To Guarantee at Least 6 Months Of Immunity

READ | 'Sputnik V' Vaccine Trial: 14% Volunteers Claim Side-effects, Says Russian Health Min

" Lancet has invited authors of Russian vaccine study to respond to questions raised in open letter by Enrico Bucci. We continue to follow situation closely," journal said.

"We encour scientific debate on papers we have published, and are aware of open letter on Russian vaccine trial by Loguv et al. We have shared letter directly with authors and encourd m to eng in scientific discussion," y continued.

Responding to invitation, Russian developers have sent ir responses promising ir western colleagues to provide access to health records of certain volunteers, so that all existing issues are clarified.

"We would like to emphasize that all presented data were obtained in experiments and double checked," letter read as stated by Russian news ncy TASS.

" coincidences that emerged, especially at early points (values are low and are close to baseline), are associated with discreteness of data, as well as with small number of participants in groups. We ackwledged this as a limitation of study in discussion section of Article," letter added.

"We confirm that individual participant data will be made available on request to DYL and that after approval of a proposal, data can be shared through a secure online platform," Russian scientists said.

criticism of vaccine seemingly comes in light of absence of eugh data for western researchers to ratify vaccine. Also re are concerns about premature approval of vaccine by Russian Government as  vaccine had t even started phase 3 trials, r had any results on earlier st trials been published when it was already approved by Russian Government and Vladimir Putin's daughter dosed. However, reports state that vaccine is w in phase 3 human clinical trials.

Russia's zootic diseases and flu department head Alexander Ryzhikov on Thursday, September 17 revealed that Suptnik V does t provide life-long immunity but guarantees at least 6 months of cover. Russian health minister Mikhail Murashko had informed that one in seven volunteers who have received a dose of indigeus COVID-19 vaccine have complained of side effects; including weakness, fever and muscle pain. He told a Russian daily that more than 300 people have already received 'Sputnik V' vaccine as part of three-phase trial, adding that 14 percent have complained about ir health. According to minister, side effects are predicted and usually disappear after a day or a maximum day and a half.

However, Russian President Vladimir Putin while making anuncement of vaccine in August claimed that his daughter was administered same vaccine and he had said, "She feels well, and concentration of antibodies is high."

READ | Russia Confirms Deal With India To Supply 100 Million Doses Of 'Sputnik V' COVID Vaccine

READ | COVID-19: Over 300 Volunteers Iculated With Sputnik V, Mild Side-effects Detected